Literature DB >> 15374000

Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation.

Mikako Fujita1, Hirofumi Akari, Akiko Sakurai, Akiko Yoshida, Tomoki Chiba, Keiji Tanaka, Klaus Strebel, Akio Adachi.   

Abstract

While the Vif protein of human immunodeficiency virus type 1 (HIV-1) is essential for viral replication in non-permissive cells, it is rapidly degraded intracellularly. We have previously suggested that the rapid turn-over of Vif is biologically meaningful to prevent detrimental effects of this protein at high expression levels. We now studied the mechanism of Vif degradation by examining the blocking effect of protease inhibitors in pulse/chase experiments and by monitoring the extent of Vif ubiquitination. The rapid turn-over of Vif could be blocked by proteasome inhibitors, and Vif was highly ubiquitinated. Cytoskeletal Vif was found to be more stable than soluble cytosolic Vif. These degradation characteristics of Vif were cell type-independent and observed in both non-permissive and permissive cells. Characterization of a series of vif deletion mutants showed that amino acids predicted to be important for formation of beta-strand structures (amino acid nos. 63-70 and 86-89) were critical for maintaining a normal expression level of Vif and for viral infectivity. Finally, we performed comparative stability analysis of the four HIV-1 accessory proteins. Vif was unique in its short half-life and in the magnitude of the degradation. Taken together, we conclude that the proteasome degradation of HIV-1 Vif is a virologically important process and crucial for the function of Vif.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15374000     DOI: 10.1016/j.micinf.2004.04.011

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  31 in total

Review 1.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

2.  Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.

Authors:  Craig Pace; Jean Keller; David Nolan; Ian James; Silvana Gaudieri; Corey Moore; Simon Mallal
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 3.  Advances in the structural understanding of Vif proteins.

Authors:  Pierre Barraud; Jean-Christophe Paillart; Roland Marquet; Carine Tisné
Journal:  Curr HIV Res       Date:  2008-03       Impact factor: 1.581

4.  N-terminal hemagglutinin tag renders lysine-deficient APOBEC3G resistant to HIV-1 Vif-induced degradation by reduced polyubiquitination.

Authors:  Yudi Wang; Qiujia Shao; Xianghui Yu; Wei Kong; James E K Hildreth; Bindong Liu
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

5.  Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.

Authors:  Tao Zuo; Donglai Liu; Wei Lv; Xiaodan Wang; Jiawen Wang; Mingyu Lv; Wenlin Huang; Jiaxin Wu; Haihong Zhang; Hongwei Jin; Liangren Zhang; Wei Kong; Xianghui Yu
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

6.  CBFβ enhances de novo protein biosynthesis of its binding partners HIV-1 Vif and RUNX1 and potentiates the Vif-induced degradation of APOBEC3G.

Authors:  Eri Miyagi; Sandra Kao; Venkat Yedavalli; Klaus Strebel
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

7.  Core Binding Factor β Protects HIV, Type 1 Accessory Protein Viral Infectivity Factor from MDM2-mediated Degradation.

Authors:  Yusuke Matsui; Keisuke Shindo; Kayoko Nagata; Noriyoshi Yoshinaga; Kotaro Shirakawa; Masayuki Kobayashi; Akifumi Takaori-Kondo
Journal:  J Biol Chem       Date:  2016-10-07       Impact factor: 5.157

8.  Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif.

Authors:  Sandra Kao; Ritu Goila-Gaur; Eri Miyagi; Mohammad A Khan; Sandrine Opi; Hiroaki Takeuchi; Klaus Strebel
Journal:  Virology       Date:  2007-09-06       Impact factor: 3.616

9.  Regulation of Vif mRNA splicing by human immunodeficiency virus type 1 requires 5' splice site D2 and an exonic splicing enhancer to counteract cellular restriction factor APOBEC3G.

Authors:  Dibyakanti Mandal; Colin M Exline; Zehua Feng; C Martin Stoltzfus
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

10.  Transmitted/Founder HIV-1 Subtype C Viruses Show Distinctive Signature Patterns in Vif, Vpr, and Vpu That Are Under Subsequent Immune Pressure During Early Infection.

Authors:  Raabya Rossenkhan; Iain J MacLeod; Zabrina L Brumme; Craig A Magaret; Theresa K Sebunya; Rosemary Musonda; Berhanu A Gashe; Paul T Edlefsen; Vlad Novitsky; M Essex
Journal:  AIDS Res Hum Retroviruses       Date:  2016-07-26       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.